Certain phthalate esters and hypolipidemic agents are known to induce morphological and biochemical changes in the liver of rodents, which have been associated with an increased incidence of hepatocellular tumors in these species. There is evidence that hypolipidemic agents do not induce these effects in either subhuman primates or man. The oral and intraperitoneal administration of di(2-ethylhexyl) phthalate (DEHP) to the marmoset monkey at doses up to 5 mmole DEHP/kg body weight/day for 14 days did not induce morphological or biochemical changes in the liver or testis comparable with those obtained in rats given the same amount of DEHP. In the marmoset, the excretion profile of [14C]-DEHP following oral, IP, and IV administration and the lower tissue levels of radioactivity demonstrated a considerably reduced absorption in this species compared to the rat.
Introduction
Di(2-ethylhexyl) phthalate (DEHP) and di(2-ethylhexyl) adipate (DEHA) are considered to be of low acute toxicity in a variety of animal species including man. However, repeat, oral administration of DEHP at high doses to rodent species produced biochemical and morphological changes in the liver (1) and testis (2) . Recently DEHP was reported to induce liver tumors in F344 rats and B6C3F1 mice and DEHA in B6C3F1 mice in 2-year feeding experiment at maximally tolerated doses, whereas several other substances related to phthalic acid did not (3) . Previous carcinogenicity studies on various phthalate esters had not shown similar effects at lower dose levels, but their validity has been questioned (4).
Recent studies have confirmed an absence of covalent binding of DEHP and DEHA with DNA (5) , which in conjunction with other negative short-term tests for mutagenicity gives additional support for the alternative hypothesis of reactive oxygen produced by the, persistent proliferation of liver peroxisomes (6) as the initiator of the neoplastic transformation of liver cells. A critical factor in extrapolating from rodents to man is whether these effects occur in other species (7) . Studies with the hypolipidemic drug ciprofibrate in several species showed peroxisome induction to be a dose-dependent rather than a species-specific phenomenon (8) . A marked reduction in hepatic peroxisomal response has been observed in the Syrian hamster compared to the rat with DEHP (9) , and similar reduced hepatic responses have been reported for the hypolipidemic agents clobuzarit (10) and clofibrate (11) in the subhuman primate species, the marmoset.
A preliminary report of a long-term chronic toxicity study of clofibrate in the marmoset at dose levels which produced hepatocellular tumors in the rat has, after 7 years, provided no evidence of hepatocellular carcinoma in this subhuman primate species (12) .
A lack of peroxisome induction in human liver biopsies removed from patients receiving therapeutic doses of hypolipidemic agents has also been reported (13 
Hepatic Enzyme Activity
Liver was homogenized in four volumes of 0.25 M sucrose/5 mM Tris-HCI (pH 7.4). The liver homogenate was then fractionated into a large particulate fraction (nuclei, mitochondria, peroxisomes, and lysosomes), a microsomal fraction, and cytosol. Several parameters were measured in the relevant subcellular preparations. Only the following are reported: catalase (15); microsomal cytochrome P-450 and cytochrome b5 (16) ; microsomal ethoxycoumarin-O-deethylation (17) and lauric acid hydroxylation (18); CN-insensitive palmitoyl CoA oxidation (19) and a-glycerophosphate dehydrogenase (20) .
Plasma Clinical Chemistry
Plasma triglyceride and cholesterol were measured as previously described (14) .
Microscopy
Light Microscopy. Liver (left caudate and papillary lobes from the rat and right median and papillary lobes from the marmoset), kidney (left), pituitary, and testes were fixed in buffered formol saline, embedded in paraffin wax, and 5.5 ,um sections stained with hematoxylin and eosin.
Electron Microscopy. Sections of the liver (right median lobe from the rat, right median and left lobes from the marmoset) were fixed in modified Karnovsky's mixed formaldehyde, gluteraldehyde fixative, and 1 mm slices postfixed in 1% buffered osmium tetroxide, dehydrated in graded acetones and embedded in Araldite resin (Ciba Geigy Ltd). Sections (1 jim) were stained with toluidine blue and used to select suitable areas for electron microscopy. Ultrathin sections (70-90 nm) stained with uranyl acetate and lead citrate were assessed visually, and micrographs recorded at x 24,900 magnification, for morphometric analysis of peroxisomes using a test grid of 320 points (21) .
Preparation of Samples for Determination of Radioactivity
Urine. Urine samples were diluted to a standard volume (25 mL) with water, and duplicate aliquots were diluted to 1.0 mL with methanol prior to scintillation counting.
Feces, Tissues, and Blood. Fecal samples were freeze-dried overnight, and duplicate samples (approximately 50 mg) were combusted in a 306B Tri-Carb sample oxidizer (Packard Instruments Limited). Tissues, homogenized with an equal weight of water, and samples of blood (60-320 mg) absorbed on to cellulose pads, were combusted as above.
Measurement of Radioactivity
Radioactivity was determined by liquid scintillation counting of prepared samples by use of a Tri-Carb 460CD microprocessor-based liquid scintillation spectrometer (Packard Instruments Limited), automatically corrected for background and counting efficiencies (external standard quench correction curve data with 226Ra as a gamma source). Samples were counted to a statistical precision of 1%.
Results and Discussion
Subacute Toxicity
Most of the published data on DEHP has been derived from studies with rodents. This study has compared the The asterisk (*) denotes significantly different from control, p < 0.05.
effects of the subacute administration of DEHP in a rodent species (rat) with those in a primate species (marmoset). The two best documented effects of DEHP in the rat are testicular atrophy and hepatomegaly. The present data demonstrate a reduction in body weight gain, testicular atrophy, and hepatomegaly in rats after 14 days oral administration at a high dose level of DEHP (2000 mg/kg/day) ( Fig. 1) . Although marmoset body weight was affected following administration of DEHP, changes in organ weight were not detected at high dose levels of DEHP (orally 2000 mg/kg/day or IP 1000 mg/ kd/day). Induction of hepatomegaly following chronic DEHP administration has been previously studied in the dog (less affected than rat) and guinea pig (absence of effect) (25) . While the rat, mouse, guinea pig, and ferret were susceptible to testicular atrophy following exposure to DEHP and the related plasticizer dibutyl phthalate (DBP), the hamster was resistant to their gonadal effects (2) . Hepatic peroxisomes (Fig. 2 ) and peroxisomal enzymes (Fig. 3) were induced in both male and female rats, whereas the hypotriglyceridemic and hypocholesteremic effects (Fig. 4) were only observed in male but not, female rats. The induction of peroxisomes and peroxisomal enzyme activity and the hypolipidemic effects were not detected following oral or IP administration of DEHP to the marmoset. The data from this present study indicate that the interrelationship of hepatomegaly, peroxisomal induction, and hypolipidemia is complex and appears to be dose-and species-dependent. Although, in the marmoset, there was an increase in catalase activity, there was not an increase in cyanide-insensitive acyl oxidase, the peroxisome marker enzyme. Hypolipidemic agents that induce peroxisomal activity in rats showed species selectivity for this effect and notably, no peroxisome proliferation was detected in the marmoset (10) . However, other nonrodents, including primates, have been shown to be responsive to the peroxisome-inducing activity of the potent hypolipidemic drug. ciprofibrate (8) .
This study has indicated the induction of a rat hepatic cytochrome P-450 with high activity towards the C-11 and C-12 hydroxylation of lauric acid. A 10-fold increase in this activity was seen, compared to a 2-to 3-fold induction of ethoxycoumarin-O-deethylation. The (27) . Consequently, the absence of such effects in the marmoset may be indicative that, as with hypolipidemic drugs, the induction of peroxisomes by DEHP is speciesand/or dose-dependent. Therefore, the hepatocellular tumors in rodents will not occur at dose levels that do not produce the necessary perturbation of cellular biochemistry, and a threshold dose for the tumorigenicity will exist.
Disposition of DEHP in the Marmoset
Subacute Administration. In both rat and marmoset, multiple oral administrations of 14C-DEHP at 2000 mg/kg. body weight/day did not modify the proprotion of dose excreted in the urine or feces in either male or female animals. Compared with a single dose, the marmoset excreted 2% of the administered dose in the urine compared with about 50% excreted by the rat (Fig. 5) . The levels of DEHP or its metabolites in the tissues of the marmoset 24 hr after the fourteenth and final dose of
[14C]-DEHP were between one-fifth and one-tenth of the levels in the rat at the corresponding time point (Fig. 6) , confirming the reduced bioavailability of DEHP in the marmoset.
Absorption and Routes ofExcretion Following a Single Dose of DEHP The cumulative excretion in urine and feces following IV administration to marmosets shows approximately 40% of the dose excreted in urine and approximately 20% in the feces (Fig. 7) remained within the marmoset at 7 days. Following IV administration 28% of the dose remained in the lungs with minimal levels in other tissues, which probably reflects entrapment of the insoluble DEHP from the IV emulsion by the alveolar capillaries. Following IP administration, 85% of the dose remained as unabsorbed DEHP in the peritoneal cavity with minimal amounts in the tissues. The residual levels in the tissues at 7 days following oral administration of 2000 mg DEHP/kg were about one-fifth of the IV dose of 100 mg DEHP/kg (Fig.  8) . Contamination of tissue by DEHP remaining in the peritoneal cavity prevents any interpretation of the tissue levels following IP administration. When the data are expressed as milligrams of DEHP equivalents excreted in urine (Table 1) at the larger oral dose, there is a reduction in the absorption of DEHP from the intestinal tract of the marmoset. The amount excreted in urine is more consistent to that expected for a 150 to 200 mg/kg dose. While the IP route provides an alternative route for parenteral administration, it also provides only a limited absorption of material equivalent to a 300 mg/kg dose. A comparison of the blood level profiles for the three routes of administration confirms the dose-dependent absorption of DEHP in the marmoset (Fig. 9) . A 20-fold increase in the oral dose from 100 to 2000 mg/kg showed only a 2-fold increase in the amount absorbed. There is a significant difference in absorption of large Biotransformation of DEHP by the Marmoset It has been established that DEHP is hydrolyzed by nonspecific pancreatic lipases to its monoester, MEHP, which is subsequently oxidized probably by enzymes of the w, w-1 and ,-oxidation pathways to a variety of metabolites (22, 24) (Fig. 10) . Species differences in metabolism of DEHP have been reported (28) (29) (30) .
In general there are only quantitative differences rather than qualitative differences in the metabolite profiles of the phase 1 oxidations between species. However, species other than the rat appear to excrete conjugated metabolites in the urine. In the marmoset, the urinary metabolite profiles following oral administration of a sin- Table 2 ). The majority of the metabolites were excreted in mainly conjugated forms, probably glucuronides. This excretion of the conjugated metabolites is similar to other primate species, but dissimilar to the rat. In addition there were more w-1 oxidation products excreted by the marmoset compared to the rat (Table 3) .
From this study, the metabolism of DEHP by the marmoset is comparable to that of other primates (30) 
Conclusion
The data presented in this paper have demonstrated that the subacute effects of DEHP, such as hepatic peroxisome proliferation, are less in the marmoset than in the rat when a large dose of DEHP (5 mmole DEHP/kg/ day) is administered orally. The bioavailability of DEHP in the marmoset at high doses is limited. However, at the tissue levels obtained in the marmoset there was no marked biochemical or morphological change observed. At comparable tissue levels following oral administration of 200 mg/kg to the rat, there are reports of such changes (31) . Although the marmoset metabolizes DEHP, it shows the same characteristic differences from the rat as do other primate species. The marmoset appears to be less sensitive to the effects of peroxisome proliferators such as DEHP and the hypolipidemic drugs. These metabolic differences may explain this species difference. This is of particular interest because peroxisome proliferation has not been observed in liver biopsies obtained from humans who had received prolonged clinical treatment, with hypolipidemics (ca. 0.15 mmole hypolipidemic/kg/ day) (32) (33) (34) . This dose level is known to produce peroxisome proliferation acutely in the rat (in the range 0.1 to 0.25 mmole hypolipidemic/kg/day) (31) . If the marmoset reflects more accurately the response in man, then the low levels of DEHP to which man is incidentally exposed (ca. 0.0015 mmole DEHP/kg/day) should not be of toxicological significance with regard to hepatocellular carcinoma.
